132 Participants Needed

Antihypertensive Therapy for Preeclampsia

(Achieve Trial)

Recruiting at 1 trial location
RS
AT
Overseen ByAlan Tita, MD
Age: < 65
Sex: Female
Trial Phase: Academic
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should not have contraindications to labetalol and nifedipine XL, which are common blood pressure medications.

What evidence supports the effectiveness of antihypertensive drugs for treating preeclampsia?

Antihypertensive drugs are recommended for severe cases of preeclampsia to lower the risk of serious complications for the mother, such as central nervous system issues. Drugs like labetalol and methyldopa are commonly used and have been shown to be effective in managing high blood pressure in these situations.12345

Is antihypertensive therapy safe for use in preeclampsia?

Medications like methyldopa, labetalol, and nifedipine are considered safe for treating high blood pressure in pregnancy, including preeclampsia. However, some drugs like angiotensin converting enzyme inhibitors and angiotensin receptor blockers should be avoided during pregnancy.34678

How does antihypertensive drug therapy for preeclampsia differ from other treatments?

Antihypertensive drug therapy for preeclampsia is unique because it focuses on managing high blood pressure during pregnancy using medications like hydralazine, labetalol, and methyldopa, which are considered safe and effective. Unlike other treatments, it does not address the underlying cause of preeclampsia, and the ultimate solution for severe cases is often early delivery.3591011

What is the purpose of this trial?

The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.

Research Team

RS

Rachel Sinkey, MD

Principal Investigator

University of Alabama at Birmingham

Eligibility Criteria

The ACHIEVE Trial is for pregnant women with high blood pressure disorders, including gestational hypertension or non-severe preeclampsia. Eligible participants are those between 23 and 35+6 weeks of pregnancy, expecting a single baby or twins, without severe preeclampsia or other complications that require immediate delivery.

Inclusion Criteria

Prenatal care or healthcare visit with documented blood pressure at less than 21 weeks gestation
You are not showing signs of severe preeclampsia or need to deliver the baby right away when you join the study.
You are pregnant with one baby or with twins, and your pregnancy is at least 14 weeks along.
See 5 more

Exclusion Criteria

I cannot take labetalol or nifedipine XL due to adverse reactions.
Your baby is smaller than most babies at the time of enrollment.
I have new headaches or vision problems that medication doesn't help.
See 9 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive antihypertensive treatment to maintain blood pressure below 140/90 mmHg

Up to 14 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 weeks

Treatment Details

Interventions

  • Antihypertensive treatment
Trial Overview This trial tests if lowering blood pressure below 140/90 mmHg in pregnant women with hypertension can extend the duration of their pregnancy. It's a randomized study where some will receive antihypertensive treatment to achieve this target.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Antihypertensive treatment for a BP goal of less than 140/90 mmHg
Group II: Usual CareActive Control1 Intervention
Antihypertensive treatment only if BP ≥ 160/110 mmHg

Antihypertensive treatment is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Antihypertensive medications for:
  • Hypertension in pregnancy
  • Preeclampsia
🇺🇸
Approved in United States as Antihypertensive medications for:
  • Hypertension in pregnancy
  • Preeclampsia
  • Chronic hypertension
🇨🇦
Approved in Canada as Antihypertensive medications for:
  • Hypertension in pregnancy
  • Preeclampsia

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Findings from Research

Mild chronic hypertension in pregnancy generally has a better prognosis than preeclampsia, and while antihypertensive therapy is recommended for severe cases, it may not significantly improve outcomes in mild cases.
Alpha-methyl-dopa is the preferred initial oral antihypertensive medication during pregnancy, as it has not shown adverse short-term or long-term effects on the fetus or neonate, making it a safe option for managing high blood pressure in pregnant women.
[Treatment of hypertensive diseases in pregnancy--general recommendations and long-term oral therapy].Rath, W.[2013]
Severe hypertension in pregnancy (systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg) should be treated with antihypertensive therapy to reduce the risk of serious complications, with parenteral hydralazine and labetalol being the most supported options.
There is no clear consensus on treating non-severe hypertension (systolic BP 140-159 mmHg or diastolic BP 90-109 mmHg) due to insufficient evidence from trials, and while treatment may lower high BP, it could also negatively impact fetal growth.
How to manage hypertension in pregnancy effectively.Magee, LA., Abalos, E., von Dadelszen, P., et al.[2023]
Recent studies have shown promising results in screening for preeclampsia before symptoms appear, which could improve early detection and management of hypertension during pregnancy.
While first-line medications for treating hypertensive complications of preeclampsia remain largely unchanged due to their established safety and efficacy, new second-line drugs have demonstrated effectiveness and safety, but further long-term studies are needed to determine if they can replace current standards.
Pathophysiology and medical management of systemic hypertension in preeclampsia.Frishman, WH., Veresh, M., Schlocker, SJ., et al.[2019]

References

[Treatment of hypertensive diseases in pregnancy--general recommendations and long-term oral therapy]. [2013]
How to manage hypertension in pregnancy effectively. [2023]
Pathophysiology and medical management of systemic hypertension in preeclampsia. [2019]
Blood pressure medication use and postpartum hospital readmission among preeclampsia patients. [2023]
Pharmacotherapeutic options for the treatment of preeclampsia. [2019]
Hypertension in pregnancy. [2011]
[Hypertension in pregnancy]. [2007]
Antihypertensive drugs in pregnancy. [2011]
9.Czech Republicpubmed.ncbi.nlm.nih.gov
[Hypertension and its treatment in pregnancy]. [2006]
[Pre-eclampsia treatment according to scientific evidence]. [2011]
11.United Statespubmed.ncbi.nlm.nih.gov
Pharmacologic approaches for the management of systemic hypertension in pregnancy. [2005]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security